• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Mannatech Reports Financial Results for Third Quarter 2024

    11/12/24 4:48:00 PM ET
    $MTEX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $MTEX alert in real time by email

    Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024.

    Third Quarter Highlights

    • Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowing demand in Asia due to weakened economic conditions, relative to the prior year.
    • Gross profit as a percentage of net sales decreased to 74.5% for the three months ended September 30, 2024, as compared to 79.6% for the same period in 2023, some of the increase in costs were related to increased freight costs related to back ordered items and running sales promotions on products thereby reducing our gross profit margin.
    • Commission expenses for the three months ended September 30, 2024 decreased by 2.0%, or $0.2 million, to $12.2 million, as compared to $12.4 million for the same period in 2023. Commissions are earned from sales. Commission expenses in dollar terms decreased during the three months ended September 30, 2024 primarily due to a decline in our sales. For the three months ended September 30, 2024, commissions as a percentage of net sales increased to 38.3% from 38.2% for the same period in 2023. The increase in commissions as a percentage of sales was due to sales promotions during the period.
    • For the three months ended September 30, 2024, selling and administrative expenses decreased by $2.8 million, or 21.8%, to $9.8 million, as compared to $12.6 million for the same period in 2023. The decrease in selling and administrative expenses was the result of a $0.9 million reduction in payroll costs, a $0.6 million decrease in marketing costs, a $0.6 million decrease to bad debt, a $0.3 million decrease in professional and consulting fees, a $0.2 million decrease in office expenses, $0.1 million decrease in depreciation expense and a $0.1 million decrease in travel and entertainment costs. Selling and administrative expenses, as a percentage of net sales, for the three months ended September 30, 2024 decreased to 31.0% from 38.6% for the same period in 2023.
    • Income from operations was $0.9 million for the three months ended September 30, 2024 as compared to $0.2 million in the same period last year. The increase in operating income in 2024, was primarily a result of decreases in the company's selling and administrative expenses as described in the previous paragraph.
    • Income tax benefit was $0.4 million for the three months ended September 30, 2024 as compared to income tax expense of $0.5 million in the same period last year.
    • Net loss was $0.3 million for the three months ended September 30, 2024, or $0.17 per diluted share, as compared to net income of $18,000, or $0.01 per diluted share for the three months ended September 30, 2023.
    • As of September 30, 2024, the company's cash and cash equivalents increased 57.2%, or $4.4 million, to $12.2 million from $7.7 million as of December 31, 2023. Operations provided $2.5 million cash for the nine months ended September 30, 2024 compared to a use of $1.0 million cash for the same period in 2023. Acquisition of property and equipment decreased for the nine months ended September 30, 2024, to $0.4 million as compared to $0.5 million for the same period in 2023. Financing activities provided $2.9 million of cash during the nine months ended September 30, 2024. This increase consisted of $3.6 million in gross loan proceeds and use of $0.7 million for the repayment of finance lease obligations and other long-term liabilities. For the nine months ended September 30, 2023, $1.6 million was used related to payments for dividends of $0.7 million, repurchase of common stock of $0.2 million and $0.7 million for the repayment of lease obligations and other long-term liabilities. Additionally, foreign exchange effects decreased the Company's cash position by $0.6 million in the nine months ended September 30, 2024, as compared to a $2.3 million effect in the same period in 2023.
    • The approximate number of new and continuing independent associate and preferred customer positions held by individuals in Mannatech's network and associated with purchases of its packs or products as of September 30, 2024 was approximately 136,000, as compared to 146,000 in the same period of 2023. Recruiting new associates and preferred customers decreased 28.1% in the third quarter of 2024 as compared to the third quarter of 2023.

    Landen Fredrick, President and CEO, noted that, "Although the third quarter of 2024 provided our highest revenue quarter in 2024, we continued to battle demand weakness in the third quarter across our global operations, with the most significant impact in the Asia/Pacific region due to ongoing economic challenges. Despite anticipating continued economic difficulties for the rest of 2024, we are committed to increasing our revenue by growing our team of sales associates and expanding our base of preferred customers, all while keeping costs under strict cost controls."

    Non-GAAP Financial Measures

    In addition to results presented in accordance with GAAP, this press release and related tables include certain non-GAAP financial measures, including a presentation of Constant dollar measures. The company discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations.

    The company believes that these non-GAAP financial measures provide useful information to investors because they are an indicator of the strength and performance of ongoing business operations. The constant currency figures are financial measures used by management to provide investors with an additional perspective on trends. Although management believes the non-GAAP financial measures enhance investors' understanding of their business and performance, these non-GAAP financial measures should not be considered an exclusive alternative to accompanying GAAP financial measures. Please see the accompanying table entitled "Non-GAAP Financial Measures" for a reconciliation of these non-GAAP financial measures.

    Safe Harbor statement

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "may," "will," "should," "hope," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "approximates," "predicts," "projects," "potential," and "continues" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

    ^ Mannatech operates in China under a cross-border e-commerce platform that is separate from its network marketing model.

    Individuals interested in Mannatech's products or in exploring its business opportunity can learn more at Mannatech.com.

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (in thousands, except share and per share information)

     

    ASSETS

    September 30, 2024 (unaudited)

     

    December 31, 2023

    Cash and cash equivalents

    $

    12,150

     

     

    $

    7,731

     

    Restricted cash

     

    939

     

     

     

    938

     

    Accounts receivable, net of allowance of $932 and $1,278

     

    22

     

     

     

    91

     

    Income tax receivable

     

    414

     

     

     

    465

     

    Inventories, net

     

    11,660

     

     

     

    14,535

     

    Prepaid expenses and other current assets

     

    2,291

     

     

     

    1,774

     

    Deferred commissions

     

    1,224

     

     

     

    2,130

     

    Total current assets

     

    28,700

     

     

     

    27,664

     

    Property and equipment, net

     

    3,118

     

     

     

    4,147

     

    Operating lease right-of-use assets

     

    2,532

     

     

     

    3,315

     

    Other assets

     

    3,674

     

     

     

    3,751

     

    Deferred tax assets, net

     

    1,913

     

     

     

    1,611

     

    Long-term restricted cash

     

    635

     

     

     

    718

     

    Total assets

    $

    40,572

     

     

    $

    41,206

     

    LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

     

    Commissions and incentives payable

    $

    8,203

     

     

    $

    8,175

     

    Accrued expenses

     

    4,803

     

     

     

    5,118

     

    Deferred revenue

     

    3,018

     

     

     

    4,786

     

    Accounts payable

     

    3,580

     

     

     

    4,010

     

    Taxes payable

     

    1,361

     

     

     

    1,521

     

    Current notes payable

     

    208

     

     

     

    240

     

    Current portion of finance lease liabilities

     

    271

     

     

     

    269

     

    Deferred tax liabilities, net

     

    —

     

     

     

    —

     

    Total current liabilities

     

    22,952

     

     

     

    25,780

     

    Long-term notes payable

     

    3,600

     

     

     

    —

     

    Operating lease liabilities, excluding current portion

     

    1,787

     

     

     

    2,582

     

    Other long-term liabilities

     

    1,483

     

     

     

    1,404

     

    Finance lease liabilities, excluding current portion

     

    751

     

     

     

    956

     

    Total liabilities

     

    30,573

     

     

     

    30,722

     

     

     

     

     

    Shareholders' equity:

     

     

     

    Preferred stock, $0.01 par value, 1,000,000 shares authorized, no shares issued or outstanding

     

    —

     

     

     

    —

     

    Common stock, $0.0001 par value, 99,000,000 shares authorized, 2,742,857 shares issued and 1,884,814 shares outstanding as of September 30, 2024 and 2,742,857 shares issued and 1,860,154 shares outstanding as of December 31, 2023

     

    —

     

     

     

    —

     

    Additional paid-in capital

     

    33,005

     

     

     

    33,309

     

    Accumulated deficit

     

    (1,073

    )

     

     

    (1,301

    )

    Accumulated other comprehensive loss

     

    (1,997

    )

     

     

    (1,015

    )

    Treasury stock, at average cost, 858,043 shares as of September 30, 2024 and 882,703 shares as of December 31, 2023

     

    (19,936

    )

     

     

    (20,509

    )

    Total shareholders' equity

     

    9,999

     

     

     

    10,484

     

    Total liabilities and shareholders' equity

    $

    40,572

     

     

    $

    41,206

     

    MANNATECH, INCORPORATED AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - (UNAUDITED)

    (in thousands, except per share information)

     

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

     

     

    2024

     

     

     

    2023

     

     

     

    2024

     

     

     

    2023

     

    Net sales

    $

    31,725

     

     

    $

    32,553

     

     

    $

    88,858

     

     

    $

    99,261

     

    Cost of sales

     

    8,105

     

     

     

    6,625

     

     

     

    20,763

     

     

     

    21,042

     

    Gross profit

     

    23,620

     

     

     

    25,928

     

     

     

    68,095

     

     

     

    78,219

     

    Operating expenses:

     

     

     

     

     

     

     

    Commissions and incentives

     

    12,893

     

     

     

    13,178

     

     

     

    36,237

     

     

     

    40,200

     

    Selling and administrative expenses

     

    9,840

     

     

     

    12,578

     

     

     

    31,293

     

     

     

    38,088

     

    Total operating expenses

     

    22,733

     

     

     

    25,756

     

     

     

    67,530

     

     

     

    78,288

     

    Income (loss) from operations

     

    887

     

     

     

    172

     

     

     

    565

     

     

     

    (69

    )

    Interest expense, net

     

    (109

    )

     

     

    (17

    )

     

     

    (196

    )

     

     

    (3

    )

    Other (expense) income, net

     

    (1,495

    )

     

     

    320

     

     

     

    495

     

     

     

    803

     

    (Loss) income before income taxes

     

    (717

    )

     

     

    475

     

     

     

    864

     

     

     

    731

     

    Income tax benefit (expense)

     

    389

     

     

     

    (457

    )

     

     

    (636

    )

     

     

    (1,214

    )

    Net (loss) income

    $

    (328

    )

     

    $

    18

     

     

    $

    228

     

     

    $

    (483

    )

    (Loss) income per common share:

     

     

     

     

     

     

     

    Basic

    $

    (0.17

    )

     

    $

    0.01

     

     

    $

    0.12

     

     

    $

    (0.26

    )

    Diluted

    $

    (0.17

    )

     

    $

    0.01

     

     

    $

    0.12

     

     

    $

    (0.26

    )

    Weighted-average common shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    1,885

     

     

     

    1,863

     

     

     

    1,885

     

     

     

    1,868

     

    Diluted

     

    1,885

     

     

     

    1,863

     

     

     

    1,885

     

     

     

    1,868

     

    Net sales by region for the three and nine months ended September 30, 2024 and 2023 were as follows (in millions, except percentages):

     

    Three Months Ended

    September 30,

     

    Nine Months Ended

    September 30,

    Region

    2024

     

    2023

     

    2024

     

    2023

    Americas

    $

    10.6

     

    33.4

    %

     

    $

    10.7

     

    32.8

    %

     

    $

    30.4

     

    34.2

    %

     

    $

    31.8

     

    32.0

    %

    Asia/Pacific

     

    18.6

     

    58.7

    %

     

     

    19.6

     

    60.1

    %

     

     

    51.6

     

    58.0

    %

     

     

    60.0

     

    60.4

    %

    EMEA

     

    2.5

     

    7.9

    %

     

     

    2.3

     

    7.1

    %

     

     

    6.9

     

    7.8

    %

     

     

    7.5

     

    7.6

    %

    Total sales

    $

    31.7

     

    100.0

    %

     

    $

    32.6

     

    100.0

    %

     

    $

    88.9

     

    100.0

    %

     

    $

    99.3

     

    100.0

    %

    Non-GAAP Financial Measures (Sales, Gross Profit and Income from Operations in Constant Dollars)

    To supplement its financial results presented in accordance with generally accepted accounting principles in the United States ("GAAP"), Mannatech discloses operating results that have been adjusted to exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, including changes in: Net Sales, Gross Profit, and Income from Operations. It refers to these adjusted financial measures as Constant dollar items, which are non-GAAP financial measures. The company believes these measures provide investors with an additional perspective on trends. To exclude the impact of changes due to the translation of foreign currencies into U.S. dollars, it calculates current year results and prior year results at a constant exchange rate, which is the prior year's rate. Currency impact is determined as the difference between the actual GAAP results and the recalculated results for the current year at the Constant dollar rates.

    The tables below reconcile third quarter 2024 and year-to-date Constant dollar net sales, gross profit and income from operations to GAAP net sales, gross profit and income from operations. (in millions, except percentages):

    Three-month period ended

    September 30, 2024

     

    September 30, 2023

     

    Constant $ Change

     

    GAAP

    Measure:

    Total $

    Translation

    Adjustment

    Non-GAAP

    Measure:

    Constant $

     

    GAAP

    Measure:

    Total $

     

    Dollar

    Percent

    Net sales

    $

    31.7

     

    $

    0.5

     

    $

    32.2

     

     

    $

    32.6

     

     

    $

    (0.4

    )

    (1.2

    )%

    Gross profit

     

    23.6

     

     

    0.4

     

     

    24.0

     

     

     

    25.9

     

     

     

    (1.9

    )

    (7.3

    )%

    Income from operations

     

    0.9

     

     

    0.1

     

     

    1.0

     

     

     

    0.2

     

     

     

    0.8

     

    400.0

    %

    Nine-month period ended

    September 30, 2024

     

    September 30, 2023

     

    Constant $ Change

     

    GAAP

    Measure:

    Total $

    Translation

    Adjustment

    Non-GAAP

    Measure:

    Constant $

     

    GAAP

    Measure:

    Total $

     

    Dollar

    Percent

    Net sales

    $

    88.9

     

    $

    1.9

     

    $

    90.8

     

     

    $

    99.3

     

     

    $

    (8.5

    )

    (8.6

    )%

    Gross profit

     

    68.1

     

     

    1.5

     

     

    69.6

     

     

     

    78.2

     

     

     

    (8.6

    )

    (11.0

    )%

    Income (loss) from operations

     

    0.6

     

    $

    0.5

     

     

    1.1

     

     

     

    (0.1

    )

     

     

    1.2

     

    (1,200.0

    )%

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241112722609/en/

    Get the next $MTEX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MTEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MTEX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mannatech Premieres Powerful New Documentary on Marathon Legend Steve Edwards

      "The Long Run" showcases a world-record journey powered by Glycan Replenishment Therapy and unmatched determination. Global health and wellness innovator Mannatech is proud to premiere Steve Edwards: The Long Run, an 11-minute short documentary chronicling the unbelievable true story of Steve Edwards—an everyday man turned endurance icon. With over 1,000 official marathons completed in record-setting average times, Edwards' legacy is one of resilience, quiet determination and the pursuit of human potential. The film debuts globally today, May 21, and is followed by an in-depth interview with Steve Edwards himself following the documentary. It is available to watch free at events.mannatech.

      5/21/25 12:16:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Fourth Quarter 2024 Financial Results

      Mannatech, Incorporated (NASDAQ: MTEX), a global health and wellness company committed to transforming lives to make a better world, today announced financial results for its fourth quarter of 2024. Quarter End Results Fourth quarter net sales for 2024 were $29.0 million, a decrease of $3.7 million, or 11.3%, as compared to $32.7 million in the fourth quarter of 2023. During the fourth quarter, the company's net sales declined 9.2% on a Constant dollar basis (a Non-GAAP financial measure); unfavorable foreign exchange during the fourth quarter caused a decrease of $0.7 million in net sales as compared to the fourth quarter of 2023. Gross profit as a percentage of net sales improved to 80

      3/26/25 6:00:00 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Financials

    Live finance-specific insights

    See more
    • Mannatech Reports Financial Results for First Quarter 2025

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its first quarter of 2025. First Quarter Highlights Net sales for the quarter ended March 31, 2025 were $26.6 million, as compared to $29.4 million for the same period in 2024, a decrease of $2.8 million, or 9.6%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $1.6 million, or 5.4%, and unfavorable foreign exchange caused a $1.2 million decrease in GAAP net sales as compared to the same period in 2024. The decline in revenues was principally due to slowing dem

      5/13/25 6:06:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Third Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its third quarter of 2024. Third Quarter Highlights Net sales for the quarter ended September 30, 2024 were $31.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $0.9 million, or 2.5%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $0.4 million, or 1.2%, and unfavorable foreign exchange caused a $0.5 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to slowi

      11/12/24 4:48:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Reports Financial Results for Second Quarter 2024

      Mannatech, Incorporated (NASDAQ: MTEX), ("Mannatech" or "Company"), global health and wellness company committed to transforming lives to make a better world, today announced financial results for its second quarter of 2024. Second Quarter Highlights Net sales for the quarter ended June 30, 2024 were $27.7 million, as compared to $32.6 million for the same period in 2023, a decrease of $4.9 million, or 14.9%. On a Constant dollar basis (see Non-GAAP Measures, below) our net sales decreased $4.2 million, or 12.9%, and unfavorable foreign exchange caused a $0.7 million decrease in GAAP net sales as compared to the same period in 2023. The decline in revenues was principally due to supply

      8/13/24 5:00:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rameson Tyler bought $126,232 worth of shares (16,288 units at $7.75), increasing direct ownership by 6% to 299,197 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      9/10/24 5:45:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care

    $MTEX
    Leadership Updates

    Live Leadership Updates

    See more

    $MTEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MTEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MTEX
    SEC Filings

    See more
    • Mannatech Announces Appointment of Robert A. Toth as Vice Chairman of the Board of Directors

      Mannatech, Incorporated (NASDAQ: MTEX) announced that on November 20, 2024, the Board of Directors of Mannatech, Incorporated (the "Board") appointed Robert A. Toth to the Board where he will serve as Vice Chairman of the Board of Mannatech, Incorporated (the "Company") effective December 1, 2024. Mr. Toth will serve as a Class III director of the Board. Mr. Toth previously served on the Company's Board between March 2008 through May 31, 2023. Mr. Toth previously served as the Chairman of the Compensation and Stock Option Plan Committee, served on the Audit Committee, the Nominating/Governance and Compliance Committee, the Science and Marketing Committee, and from August 2014 to March 201

      11/26/24 4:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Announces Appointment of James Clavijo as Chief Financial Officer

      Mannatech, Incorporated (NASDAQ: MTEX) announced that the Board of Directors appointed James Clavijo as Chief Financial Officer of Mannatech Incorporated (the "Company") effective July 1, 2024. James Clavijo brings over 25 years of experience in executive, finance, and accounting activities. He has served as CFO for biotech, medical technology, and pharmaceutical companies, including Longeveron (NASDAQ:LVGN), Guided Therapeutics (OTC:GTHP), Aeterna Zentaris (NASDAQ:AEZS), and Tri-source Pharma. Mr. Clavijo has led and advised companies with strategic plans for pharmaceutical commercialization and manufacturing, has negotiated licensing and drug development agreements, and he has advised c

      7/1/24 5:46:00 PM ET
      $AEZS
      $MTEX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medicinal Chemicals and Botanical Products
    • Mannatech Announces Retirement of Alfredo Bala and Promotion of Landen Fredrick to President and CEO

      Mannatech, Incorporated (NASDAQ: MTEX) reported that Alfredo (Al) Bala, announced his retirement as the company's CEO effective April 1, 2024. J. Stanley Fredrick, Chairman of the Board of Mannatech, Incorporated stated, "Al will continue to serve the company as an advisor focused on customer acquisition and sales growth. This transition enables Al to work more closely with our associates in the field which has always been his first love. In this new role, Al will also focus on field and leadership development, leveraging his 43 years of experience in direct sales at both the field and corporate level helping to create and develop programs dedicated to growing people and sales." Mr. Fredr

      3/13/24 7:30:00 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Mannatech Incorporated

      SC 13G - MANNATECH INC (0001056358) (Subject)

      11/1/24 11:44:29 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      1/13/23 11:03:46 AM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Mannatech Incorporated (Amendment)

      SC 13G/A - MANNATECH INC (0001056358) (Subject)

      2/7/22 6:32:28 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: SEC Form 4 filed by Director Toth Robert

      4/A - MANNATECH INC (0001056358) (Issuer)

      3/17/25 1:23:48 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Fredrick J Stanley was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 0.76% to 356,975 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:18 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Toth Robert was granted 2,686 units of Common Stock Par Value $0.0001 Per Share, increasing direct ownership by 3% to 91,130 units (SEC Form 4)

      4 - MANNATECH INC (0001056358) (Issuer)

      1/6/25 12:37:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Mannatech Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MANNATECH INC (0001056358) (Filer)

      5/13/25 5:06:07 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 10-Q filed by Mannatech Incorporated

      10-Q - MANNATECH INC (0001056358) (Filer)

      5/13/25 4:57:24 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form DEF 14A filed by Mannatech Incorporated

      DEF 14A - MANNATECH INC (0001056358) (Filer)

      4/22/25 5:01:03 PM ET
      $MTEX
      Medicinal Chemicals and Botanical Products
      Health Care